DLA Piper represents Parnell Pharmaceuticals in initial public offering
DLA Piper has advised Parnell Pharmaceuticals Holdings (PARN) in its initial public offering on NASDAQ.
PARN, an Australian-based veterinary pharmaceutical company with US operations located in Kansas City, Kansas, focuses on developing, manufacturing and commercialising innovative animal health solutions.
The company currently markets five products for companion animals and production animals in 14 countries and augments its pharmaceutical products with its proprietary software platforms.
The international DLA Piper team leading this cross-border offering included Andrew Gilbert, David Schwartz and Kirsten O’Donnell in New Jersey; Julia Kovacs and Linda Thomas in Baltimore; Michael Greenberg in New York; Rita Patel in Washington DC; David Morris, Simone Mitchell and Leah O’Brien in Sydney; and James Newnham in Melbourne.
News from DLA Piper
News from The Lawyer
Briefings from DLA Piper
The Financial Report — Fed study questions new money market rules; Singapore updates audit committee guidebook; and more
DLA Piper has released the latest version (Volume 3, No.16) of The Financial Report, featuring news and analysis from across the financial sector.
The National Bank of Ukraine has toughened requirements for the mandatory sale of international currency proceeds that was temporarily introduced in November 2012.
Analysis from The Lawyer
Shearman & Sterling is making its presence felt in the City, squaring up to magic circle firms and looking to muscle in on key relationships. Private equity house Bridgepoint is one outfit that has had its head turned by the US firm.
A new breed of lawyer is smoothing the path for companies entering emerging or unstable jurisdictions